Navigation Links
Drew Barrymore Announces US$1 Million Donation on Oprah
Date:3/3/2008

r; the agency now estimates it needs at least US$500 million more than anticipated last year to meet its 2008 operational budget of US$3.4 billion. The half-billion dollar increase is solely due to the sharp hike in food and transport costs over the last few months.


'/>"/>
SOURCE Friends of the World Food Program
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
2. PreMD Inc. Announces Debenture Financing
3. Caregivers are Honored as CVS/pharmacy Announces Winners of the For All the Ways You Care Contest
4. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
5. Therap Services Announces Release 7.2 for the Developmental Disability Community
6. CVS Caremark All Kids Can Program Announces the Opening of a Boundless(TM) Playground in Dallas to Serve Children of all Abilities
7. Nightingale announces US$12.3 million sale of its Therapist Helper business
8. Hillenbrand Industries, Inc. Announces Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
9. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
10. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
11. Childrens Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...erapy given in conjunction with cancer vaccines ma...mproving the effectiveness of this promising type ...hers in the Duke Comprehensive Cancer Center. , ...hat suppress immune function and we speculated tha... in conjunction with vaccines, which work by boost...
(Date:5/15/2008)...y 15 /PRNewswire-FirstCall/ -- Digital Power,Corpo...y announced its,financial results for the first qu...ed revenue of $3,169,000 for the quarter ended,Mar...for the same quarter,last year. An operating loss ...rted, compared to an operating profit of $25,000 f...
(Date:5/15/2008)...PRNewswire/ -- JumpStart Inc., the Northeast Ohio,...the growth of innovative,early-stage businesses an...,$350,000 in CerviLenz(TM), Inc. The Cleveland-bas...Drug Administration cleared medical,device that al...th in,pregnant women, which has been established b...
(Date:5/15/2008)...Clinton Promise Comprehensive Healthcare Plans, Lo...e, Private Funding, KIRKLAND, Wash., May 15 /PRNe...oduce healthcare reform? "Probably," says Cameron ...nced long term care insurance,agencies, LTC Financ...Clinton,s, or perhaps McCain,s -- cover all health...
Breaking Medicine News(10 mins):Health News:Chemotherapy might help cancer vaccines work 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2
...es have shown inhaled corticosteroids can reduce t... patients experience.// However, results from a st...f Washington show otherwise. Researchers studied m...re prescribed inhaled corticosteroids for at least...
...hows an antiparasitic drug appears to help people ...solium.// Researchers speculated treatment with t...ht might help these patients reduce the number of ...d 120 patients with signs of the living parasite i...
...discovery could help give insight into a very dead...n the gene // that codes for the progesterone rece...e PGR had previously been linked to a higher ovari... cancer risk in women who carry it. Researchers us...
...es have shown inhaled corticosteroids can reduce t... patients experience.// However, results from a st...f Washington show otherwise. Researchers studied m...re prescribed inhaled corticosteroids for at least...
Other Medicine News:
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)...hase II Data Presented at ASCO Showed Acceptable T...e of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N....motherapeutic agent eribulin mesylate (E7389) demo...on of women with locally advanced or metastatic,br...r Phase II clinical,trial. The study also suggests...
(Date:5/15/2008)... - Unprecedented amount of research reflects dep...rs worldwide to develop new treatments for ...y session to highlight impact of Zometa(R), the le...nts with early-stage breast cancer, - Four oral s...ontinuous, inhibitor of mTOR, including first resu...
(Date:5/15/2008)...od pressure reductions demonstrated in Blacks, His...tes and Obese Individuals, PARSIPPANY, N.J., May ... today that data presented at the American Society... Meeting (ASH 2008) in New,Orleans demonstrated th...ine and olmesartan medoxomil) safely and effective...
Breaking Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 1EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 2EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 3EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 4Phlo Affiliate Names Director Of Marketing 1720 1Phlo Affiliate Names Director Of Marketing 1720 2Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 1Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 2Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 3Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 4Researchers analyze domestic violence deaths 5752 1Researchers analyze domestic violence deaths 5752 2Researchers analyze domestic violence deaths 5752 3
...harmaceuticals Inc.,(TSX: TLN) announced today tha...ial investigating ECO-4601 in advanced cancer,pati... American,Society of Clinical Oncology (ASCO) Annu...se escalation portion of the study, 14,patients (t...lioma), that had completed and not responded to th...
...res favorably with,the activity of mTOR inhibitors...Call/ - AEterna,Zentaris Inc. , a global biopharma...oncology, today announced that its partner,Keryx ...ase 1 and,Phase 2 results for perifosine, an oral ..., for the treatment of patients with,advanced sarc...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: